This stratification approach parallels successful response-adaptive strategies in other malignancies, such as trastuzumab escalation in residual HER2+ breast cancer (29) or de-escalation in HPV+ oropharyngeal cancer. Here, ERBB2 is linked to oropharynx cancer.